Genomic, Epigenomic, and Transcriptomic Profiling towards Identifying Omics Features and Specific Biomarkers That Distinguish Uterine Leiomyosarcoma and Leiomyoma at Molecular Levels

Table 2

Numbers of differentially methylated CpG sites in LM and LMS compared to normal metrium (NM) tissues.

Feature	# of CpG probes	Leiomyoma (LM)		Leiomyosarcoma (LMS)
		Hypermethylated ()	Hypomethylated ()	Hypermethylated ()	Hypomethylated ()
Gene feature groups
Intergenic	115,382	4,910 (4.3%)	2,776 (2.4%)	4,533 (3.9%)	33,513 (29.0%)
TSS1500	67,542	1,841 (2.7%)	1,059 (1.6%)	1,614 (2.4%)	9,741 (14.4%)
TSS200	50,513	877 (1.7%)	415 (0.8%)	1,043 (2.1%)	3,625 (7.2%)
5′UTR and 1st exon	63,745	1,504 (2.4%)	913 (1.4%)	2,025 (3.2%)	6,383 (10.0%)
Gene body	157,160	4,539 (2.9%)	3,894 (2.5%)	7,072 (4.5%)	24,809 (15.8%)
3′UTR	17,170	382 (2.2%)	453 (2.6%)	750 (4.4%)	2,478 (14.4%)
Total	471,512	14,053 (3.0%)	9,510 (2.0%)	17,037 (3.6%)	80,549 (17.1%)
Relation to CGI
CGI	145,443	3,848 (2.6%)	884 (0.6%)	6,541 (4.5%)	6,612 (4.5%)
Shore and shelf	156,254	5,230 (3.3%)	2,960 (1.9%)	6,180 (4.0%)	26,231 (16.8%)
Open sea	169,815	4,975 (2.9%)	5,666 (3.3%)	4,316 (2.5%)	47,706 (28.1%)
Total	471,512	14,053 (3.0%)	9,510 (2.0%)	17,037 (3.6%)	80,549 (17.1%)

Outside of island, shore, and shelf.
of LM: average of the β values of three LM samples − average of the β values of three NM samples.
of LMS: average of the β values of three LMS samples − average of the β values of three NM samples.